comparemela.com

Latest Breaking News On - Denovium engine - Page 2 : comparemela.com

Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci

Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Shanghai
China
Sean-mcclain
Deniz-kural
Ohan-dai
Totient-inc
Denovium-engine
Chief-business-officer
Viva-biotech
Langhua-pharmaceutical
ஷாங்காய்
சீனா

AbSci Announces Strategic Investment by Merck Global Health Innovation Fund

AbSci Announces Strategic Investment by Merck Global Health Innovation Fund News provided by Share this article Share this article VANCOUVER, Wash., Feb. 22, 2021 /PRNewswire/  AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and potential discovery collaborations with Merck Research Laboratories. AbSci founder and CEO Sean McClain said, It has been terrific to work with Merck on many levels. We are pleased to be able to add value and bring solutions to tough problems. With the success of our initial projects, as well as this investment from Merck GHI, we have set in place a foundation upon which to build out a broad and mutually beneficial partnership with Merck. Everyone we have worked with at Merck shares the goal of helping the most patients with the best medicines as quickly as possible.  

Vancouver
British-columbia
Canada
Sean-mcclain
Prem-tumkosit
Digital-health
Merck-research-laboratories
Merck-global-health-innovation-fund
Merck-research
Next-horizon
Managing-director
Denovium-engine

AbSci purchases San Diego artificial intelligence startup Denovium

AbSci purchases San Diego artificial intelligence startup Denovium Growing company to relocate to Columbia Tech Center in May By Will Campbell, Columbian Assistant Metro Editor Published: January 13, 2021, 6:30am Share: Sean McClain, founder and CEO of AbSci in downtown Vancouver. (Amanda Cowan/The Columbian files) Vancouver-based biotech company AbSci announced Tuesday that it purchased a deep-learning artificial intelligence startup called Denovium, based in San Diego. The acquisition will help AbSci work toward its “grand vision,” said founder and CEO Sean McClain: using mass data and artificial intelligence, or AI, to create new molecules with a click of a button without the lengthy process of trial testing. It will help the company create new disease-fighting drugs much faster.

San-diego
California
United-states
Vancouver
British-columbia
Canada
Sean-mcclain
Imad-ajjawi
Jay-inslee
Columbia-tech-center
Strategic-reserve-fund
Denovium-engine

AbSci acquires AI startup Denovium to boost synthetic biology platform

AbSci acquires AI startup Denovium to boost synthetic biology platform January 12, 2021 at 7:35 am AbSci CEO and Founder Sean McClain. (AbSci Photo) AbSci has acquired Denovium, a 6-person bootstrapped startup out of San Diego that uses deep learning to analyze the function and behavior of proteins. The deal will help bolster AbSci’s synthetic biology platform. The company’s “Protein Printing” technology is used to discover and manufacture complex biological molecules such as antibodies and insulin. AbSci plans to integrate the Denovium Engine into its own development capabilities. Terms of the acquisition were not disclosed. Vancouver, Wash-based AbSci is coming off a $65 million investment round raised in October; the company has raised $100 million to date. It employs 85 people and plans to double headcount this year after more than doubling its revenue in 2020. The company is led by CEO and founder Sean McClain, who started AbSci in 2011.

San-diego
California
United-states
Vancouver
British-columbia
Canada
Sean-mcclain
Founder-sean
Absci-photo
Denovium-engine
Wash-based-absci

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.